Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer

Immunotherapy has been widely utilized in multiple tumors, however, its efficacy in the treatment of triple-negative breast cancers (TNBC) is still being challenged. Meanwhile, functions and mechanisms of RNA binding proteins in regulating immunotherapy for TNBC remain largely elusive. Here we repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinrui, Zhang, Ge, Zhang, Wenjing, Bai, Lu, Wang, Luning, Li, Tiantian, Yan, Li, Xu, Yang, Chen, Dan, Gao, Wenting, Gao, Chuanzhou, Chen, Chaoqun, Ren, Menglin, Jiao, Yuexia, Qin, Hongqiang, Sun, Yu, Zhi, Lili, Qi, Yangfan, Zhao, Jinyao, Liu, Quentin, Liu, Han, Wang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613699/
https://www.ncbi.nlm.nih.gov/pubmed/35538152
http://dx.doi.org/10.1038/s41418-022-01012-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613699/
https://www.ncbi.nlm.nih.gov/pubmed/35538152
http://dx.doi.org/10.1038/s41418-022-01012-0

Ejemplares similares